Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro
1998

Combining Navelbine and Medroxyprogesterone Acetate for Breast Cancer Treatment

publication Evidence: moderate

Author Information

Author(s): K Sugiyama, M Shimizu, T Akiyama, H Ishida, M Okabe, T Tamaoki, S Akinaga

Primary Institution: Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo

Hypothesis

Does the combination of Navelbine and Medroxyprogesterone Acetate enhance the treatment efficacy against human breast carcinoma MCF-7 cells?

Conclusion

The combination of Navelbine and Medroxyprogesterone Acetate shows a synergistic effect in inhibiting the growth of breast cancer cells.

Supporting Evidence

  • The combination of Navelbine and Medroxyprogesterone Acetate was shown to be synergistic in inhibiting MCF-7 cell growth.
  • Navelbine induced G1-phase accumulation and increased expression of the CDK inhibitor p21WAF1/cIPl.
  • MPA reduced cyclin D1 protein expression, contributing to G1-phase accumulation.
  • The combined treatment was effective in other breast cancer cell lines as well.

Takeaway

Using two medicines together can work better than using them alone to fight breast cancer cells.

Methodology

The study used isobologram and median-effect plot analyses to assess the combined effects of Navelbine and Medroxyprogesterone Acetate on MCF-7 cells in vitro.

Limitations

The study was conducted in vitro, and results may not directly translate to clinical outcomes in patients.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication